Please provide your email address to receive an email when new articles are posted on . 92%, 62% and 60% of subjects were satisfied with their outcomes at months 1, 6 and 12 post-treatment, ...
Please provide your email address to receive an email when new articles are posted on . The FDA issued a complete response letter to Galderma for the biologics license application for ...
The Food and Drug Administration (FDA) has approved letibotulinumtoxinA-wlbg, an injectable neurotoxin long used in South Korea for the treatment of moderate to severe glabellar (frown) lines in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback